Positive EMA Opinion on Pediatric Investigation Plan for PolTREG's Treg Therapy in Type 1 Diabetes
Positive EMA Opinion on Pediatric Investigation Plan for PolTREG's Treg Therapy in Type 1 Diabetes
The Paediatric Committee (PDCO) of the European Medicines Agency issues positive opinion on PolTREG's Pediatric Investigation Plan (PIP) for PTG-007 in pre-symptomatic type 1 diabetes (Stage 1).
Positive opinion paves the way for potential marketing authorization in the EU and EEA.
Recommendation to expand pediatric indication to ages 3–18 years (originally 6–16 years).
In vivo data in murine models confirm preliminary safety and efficacy of CAR-TREG therapy, supporting upcoming Phase 1 clinical trials in multiple sclerosis and amyotrophic lateral sclerosis.
Gdańsk, Poland – 15 May 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, announces that the Paediatric Committee (PDCO) of the European Medicines Agency has issued a positive opinion on the Pediatric Investigation Plan (PIP) for its investigational somatic cell therapy product, polyclonal Treg lymphocytes (PTG-007), aimed at preventing symptomatic type 1 diabetes in children.
'Securing a positive opinion from the PDCO brings PolTREG one step closer to the potential approval of PTG-007 for pediatric use across the European Union and the European Economic Area. Achieving the PIP-defined clinical endpoints may serve as the basis for obtaining marketing authorization. Pre-symptomatic type 1 diabetes (Stage 1) represents a significant unmet medical need, making this therapeutic area highly attractive,' said Prof. Piotr Trzonkowski, CEO of PolTREG. 'We are also delighted by the progress in developing next-generation Tregs. The in vivo murine results obtained a few days ago using CAR-TREG lymphocytes shows the preliminary safety and efficacy of our therapy. In the coming months, we will intensively prepare to initiate a Phase 1 clinical trial in multiple sclerosis and amyotrophic lateral sclerosis,' said Prof. Piotr Trzonkowski.
The PDCO's positive opinion is based on PolTREG's original preTreg clinical trial protocol initiated in October 2024, which enrolled children aged 6–16 years in Stage 1 type 1 diabetes. In its assessment, the committee has recommended broadening the eligible population to include patients aged 3–18 years.
PolTREG combines over 12 years of clinical data confirming the safety and efficacy of polyclonal Treg therapies with a broad portfolio of next-generation technologies, including allogeneic Tregs, CAR-TREGs, antigen-specific Tregs, and TCR-TREGs. PolTREG is the only company with 12 years' worth of patient-safety and efficacy data for autologous polyclonal Treg therapies—data derived from clinical trials and hospital exemptions in Poland.
To read more about the clinical trials PolTREG has completed, please click on: https://poltreg.com/tregs-therapy/#publications
In parallel, PolTREG has achieved a major milestone toward its CAR-TREG program, in collaboration with AZTherapies. In vivo studies in murine models demonstrate encouraging preliminary safety and efficacy for CAR-engineered Treg lymphocytes, supporting an application for a Phase 1 clinical trial in multiple sclerosis and Amyotrophic Lateral Sclerosis in the coming months. This cellular product will be further made allogeneic in the cooperation with Swiss-based company Antion Biosciences.PolTREG manufactures its Treg therapeutics at its own GMP-certified manufacturing facility. It is the first company in the world to have administered Treg therapies to patients, and, under a hospital exemption valid in Poland, the first company to start receiving revenues from a Treg therapeutic for autoimmune disease. Its GMP manufacturing facility is one of Europe's largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines.
PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies. It can ship its wide range of cellular therapy products across Europe within 24 hours.
About PolTREG
PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies.
For more information please visit www.poltreg.com.
For further information please contact:PolTREG S.A.Prof Piotr TrzonkowskiChief Executive Officerir@poltreg.com+48 512 532 401
Important information
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Work and pensions secretary tells MPs controversial disability benefit reforms will go ahead next year
The government has told MPs it will not back down from its controversial reforms to disability benefits, which are set to be introduced to parliament later this month. More than 100 Labour MPs are thought to have concerns about the plans to cut nearly £5bn from the welfare bill by restricting personal independence payments (PIP) and the health top-up to Universal Credit. Charities say the changes will have a "catastrophic" effect on vulnerable people. Politics Hub: The chair of the Commons' Work and Pensions Committee wrote to the secretary of state, Liz Kendall, last month, calling on the government to delay the changes until a full assessment is carried out of the impact on employment, poverty and health. Labour MP Debbie Abrahams wrote that while there was a case for reform to disability benefits, "the evidence indicated [these changes] might not improve outcomes for most claimants, but instead push many into poverty and further away from the labour market". But Ms Kendall has written back, in a letter made public on Wednesday, to reject the idea because the bill needs final approval from parliament in November in order for the changes to take effect in 2026. She wrote: "We need urgent action to help people who can work, into work. With one in eight young people now not in education, employment or training and nearly 2.8 million people out of work due to long-term sickness, and spending on health and disability benefits set to rise by an additional £18bn, we must change course. "We have consistently been clear that we are not consulting on every proposal. "Instead, parliament will have the opportunity to fully debate, propose amendments to, and vote on areas where we have announced urgent reforms that are not subject to consultation. "With PIP caseload and costs forecast to continue rising, reforms are needed now to make the system sustainable, while supporting those people with the greatest needs." The government says the PIP caseload has more than doubled from 15,000 new claims per month in 2019 to 34,000. PIP is a benefit to help disabled people with the increased costs of day-to-day living. It is proposed that claimants will need to achieve four points out of eight in their assessment to qualify for the benefit, and the government says some 370,000 existing claimants will lose out when reassessed. Ms Kendall says the growth in claims means the PIP caseload will still increase by the end of the parliament. The government will also tackle what Ms Kendall called the "perverse incentive" to claim the health top-up for Universal Credit by freezing it at £97 a week for existing claimants, and slashing the rate to £50 a week for new claimants. The average loss of benefits will be £1,700 a year for some three million people. Claimants with the most serious conditions, who have been assessed as never able to work, will not be subject to reassessment, ministers say, allowing them to have peace of mind. The government will provide £1bn for targeted support schemes to help disabled people into work. But it's estimated these will help only some 70,000 people find employment. Ms Kendall said a minister in her department is engaging with disabled people and organisations about the PIP assessment process, but said: "The PIP assessment review will rightly take time and require extensive engagement, and we cannot wait for its conclusion to make the urgently needed changes to the PIP eligibility criteria." The first minister of Wales, Eluned Morgan, who is gearing up for elections next year, told Sky News she had spoken to Ms Kendall about her concerns last week. She said: "This is going to be really challenging for a lot of people in Wales. We know more people in Wales will be affected by PIP than in any other part of the country. "We do think there needs to be reform of welfare because we believe people can work should work, but in Wales we have examples of where we hold people's hands, stand by them, we help them into work, and we think that's more of a productive approach." Read more:Are tax rises inevitable after the spending review? Labour MP Richard Burgon, who has vowed to vote against the reforms, said: "This will be deeply disappointing news for all the MPs who've been urging the government to delay this decision. Instead of allowing time for proper scrutiny and meaningful dialogue with disabled people, the government has brushed aside MPs' genuine concerns. "These planned disability cuts should be scrapped - not rushed through without proper scrutiny."
Yahoo
3 hours ago
- Yahoo
SpliceBio lands $135M for a new kind of eye gene therapy
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. SpliceBio, a Spanish biotechnology company working on next-generation gene therapies, said Wednesday it raised $135 million in a Series B round to advance its lead program in Stargardt disease into further clinical testing. The startup is built around a technology that's meant to overcome a key limitation of current gene therapies. Scores of gene therapy developers use adeno-associated viruses, or AAVs, to deliver genetic cargo into the body. But because of their small size, AAVs can't carry larger corrective genes, leaving many diseases out of reach or forcing companies to come up with creative solutions. One example is in Duchenne muscular dystrophy. Because of the large size of the gene coding for the muscle-protecting protein dystrophin Duchenne patients lack, several companies, like Sarepta Therapeutics, have developed gene therapies that make a shortened form. The approach comes with drawbacks, however, as a truncated version of the protein might not work as well as the original. SpliceBio has a different workaround. The company is using two separate AAVs to send pieces of a large gene into cells. Once inside, specially engineered splicing molecules help reassemble their cargo into full-length proteins. Stargardt disease, for example, is caused by mutations to the ABCA4 gene, which is too large to stuff into an AAV. SpliceBio says its method can help the body produce a functional version of the protein that gene produces. Its lead program, SB-007, is in a Phase 1/2 trial. SpliceBio isn't the only biotech pursuing this type of approach to treat Stargardt, an inherited eye condition that causes progressive vision loss. Another European company, AAVantgarde, has a similar type of program in early-stage testing. SpliceBio's technology is based on research conducted at Princeton University, where co-founder and CEO Miquel Vila-Perelló was studying protein design and engineering. Launched in 2014 under the name ProteoDesign, the biotech is also working on additional programs in ophthalmology, neurology and other undisclosed therapeutic areas. Its Series B round was co-led by EQT Life Sciences and Sanofi Ventures, and involved seven other backers including Roche Venture Fund, New Enterprise Associates and Novartis Venture Fund. "The support from such high-quality investors underscores the strength of our programs and our unique protein splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today,' Vila-Perelló said in a statement. The company raised €50 million in a Series A round in 2022. Gene and cell therapy startups backed by the roughly two dozen investment firms BioPharma Dive tracks have secured a little over $1.1 billion in venture dollars so far in 2025. Half of those fundings have come in the form of 'megarounds' exceeding $100 million apiece, continuing an ongoing trend. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
12 hours ago
- Bloomberg
Astra's Early Test Fuels Hope for Cell Therapy Approach to Lupus
AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK drugmaker plows billions into the growing area of cell therapy called CAR-T. The medicine, which Astra gained in the takeover of Gracell Biopharmaceuticals Inc., has only just entered clinical trials. But the tiny study, conducted in Shanghai, had a stark impact on ten young volunteers whose disease wasn't controlled by earlier treatment. Six of them no longer showed signs of having lupus nine months after the one-time infusion, according to early results.
